PubMed Health⌕ Search

PubMed · 11457199

Polyhedral boranes and elemental boron: direct structural relations and diverse electronic requirements.

Abstract

Details of the electronic and structural connections between macropolyhedral boranes and elemental boron are reported. The nature of electron deficiency in the beta-rhombohedral polymorph of boron is analyzed by using a molecular fragments approach with boranes as model systems. The B57H36 molecule constructed from such an approach has three more electrons than mandated by the electron-counting rules (Balakrishnarajan, M. M.; Jemmis, E. D. J. Am. Chem. Soc. 2000, 122, 456. Jemmis, E. D.; Balakrishnarajan, M. M.; Pancharatna, P. D. J. Am Chem. Soc. 2001, 123, 4313-4323.) devised for macropolyhedral boranes. This is also confirmed by electronic structure calculations at the extended Hückel and B3LYP/6-31G levels. The aromaticity of this B57H36(3+) molecule is on par with the most stable B12H12(2-) itself, as revealed by nuclear independent chemical shift calculations. The B57 skeleton can be made electron precise by adopting a nido arrangement by eliminating an atom from the closo skeleton, so that three valence electrons will be removed. The exact site of elimination, governed by thermodynamic factors, necessitates the removal of a boron atom from any of the six symmetrically equivalent B[13] sites in the unit cell. This leads to partial occupancies, which causes disorder in packing, as revealed by X-ray structure studies. The rest of the boron atoms are distributed in icosahedral B12 fragments, whose two-electron deficiency is satisfied by the capping of extra atoms, distributed statistically in the interstitial sites. These results show that the three-dimensional network of the idealized beta-rhombohedral unit cell is not stable, unlike the electron-precise carbon polymorphs such as diamond and graphite. Thus, disorder in the form of partial occupancies, interstitial atoms, alien atoms, etc., is necessary for electron sufficiency and hence for the stability of this polymorphic form. Through these ingenious steps, all components of the unit cell attain electron sufficiency, which explains the high thermodynamic stability of the polymorph. The connection established between boranes and elemental boron in terms of their structure and distribution of electrons has important implications in understanding the structure of boron-rich solids and new strategies to utilize their diverse and technologically important properties.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E D Jemmis, M M Balakrishnarajan. 2001-05-09. Polyhedral boranes and elemental boron: direct structural relations and diverse electronic requirements.. https://doi.org/10.1021/ja0026962

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗